





Acute hypoxaemic respiratory failure in immunocompromised patients: abandon bronchoscopy or make it better?

Philippe R. Bauer¹, Sylvie Chevret² and Elie Azoulay³, on behalf of the Nine-I Investigators

Affiliations: ¹Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. ²Biostatistics, Saint Louis hospital, Paris, France. ³Intensive Care Unit, CHU Saint Louis, Paris, France.

Correspondence: Philippe R. Bauer, Mayo Clinic, Pulmonary and Critical Care Medicine, Gonda 18, 200 First Street SW, Rochester, MN, 55905, USA. E-mail: bauer.philippe@mayo.edu

@ERSpublications

The decision-making process regarding whether to perform bronchoscopy in acute respiratory failure in immunosuppressed patients is complex and does not depend solely on severity http://bit.ly/2O9cjcq

Cite this article as: Bauer PR, Chevret S, Azoulay E. Acute hypoxaemic respiratory failure in immunocompromised patients: abandon bronchoscopy or make it better?. *Eur Respir J* 2019; 54: 1902177 [https://doi.org/10.1183/13993003.02177-2019].

This single-page version can be shared freely online.

From the authors:

In their letter to the Editor, M.S. Zinter and G-S. Cheng raise concerns about the conclusion of our study that immunocompromised patients with acute hypoxaemic respiratory failure who undergo fibreoptic bronchoscopy have inferior survival relative to those who do not undergo fibreoptic bronchoscopy. They offer an alternative explanation to our findings by emphasising the role of the time-varying nature of the bronchoscopy as well as the time-varying nature of other covariates, including illness severity leading up to bronchoscopy, when performing the propensity score matching.